US EditionModerna stock plunges 18% after company lowers 2025 sales forecast by $1 billion
- Shares in Moderna fell by more than 20% after the company lowered its revenue guidance for 2025 by $1 billion, expecting revenue between $1.5 billion and $2.5 billion.
- The company plans to cut expenses by $1 billion this year, as sales of its vaccines have been lower than expected.
- Moderna's mResvia vaccine faced challenges in the market, contributing minimal sales to its total revenue for 2024, which was lower than previous guidance.
- Investors remain cautious about Moderna's future success, as the company acknowledged being too optimistic about its market entry and the performance of its products.
46 Articles
46 Articles
Moderna stock drops on lower 2025 guidance, more cost cuts
Moderna Inc. entered the new year on the heels of a worsening stock performance in 2024. The Cambridge drugmaker’s stock dropped even further after lowering its expected revenue range for 2025 during the J.P. Morgan Healthcare Conference.
Moderna Shares Crash On Sluggish COVID Demand, Cuts 2025 Revenue Forecast
This article was originally published by Tyler Durden at ZeroHedge. Shares of Moderna crashed in premarket trading after the company issued business and pipeline updates revealing sluggish demand for its Covid-19 and RSV vaccines. The weak sales environment forced the company to slash its 2025 full-year forecast, falling short of Wall Street’s average estimates. Moderna released business updates and progress across its pipeline of mRNA medicine…
Moderna Stock Drops 20% as 2025 Outlook Falls Short of Expectations
orecast, signaling a potentially challenging year ahead. The company now expects revenue for 2025 to fall between $1.5 billion and $2.5 billion, a steep reduction from its previous forecast of $2.5 billion to $3.5 billion issued in September. This adjustment is driven by a range of factors that could hinder growth as Moderna works to cut costs and expand its product portfolio. CEO Stéphane Bancel pointed to several key headwinds impacting Modern…
Why Moderna Stock Just Crashed 21% @themotleyfool #stocks $MRNA
Faced with low demand, the American pharmaceutical company is revising its forecasts downwards for 2025....
Coverage Details
Bias Distribution
- 48% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
